Reviva Pharmaceuticals Holdings Inc (NASDAQ: RVPH)’s stock price has soared by 13.80 in relation to previous closing price of 0.76. Nevertheless, the company has seen a gain of 14.43% in its stock price over the last five trading days. globenewswire.com reported 2025-03-30 that CUPERTINO, Calif., March 30, 2025 (GLOBE NEWSWIRE) — Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, announced today topline data from the long-term open label extension portion of the Phase 3 RECOVER study evaluating brilaroxazine in schizophrenia will be presented as part of an oral presentation at the 2025 Congress of the Schizophrenia International Research Society (SIRS) taking place March 29 to April 2, 2025 in Chicago, Illinois, U.S.
Is It Worth Investing in Reviva Pharmaceuticals Holdings Inc (NASDAQ: RVPH) Right Now?
The 36-month beta value for RVPH is at 0.17. Analysts have varying views on the stock, with 3 analysts rating it as a “buy,” 3 rating it as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for RVPH is 41.78M, and currently, shorts hold a 6.99% of that float. The average trading volume for RVPH on April 24, 2025 was 1.06M shares.
RVPH’s Market Performance
The stock of Reviva Pharmaceuticals Holdings Inc (RVPH) has seen a 14.43% increase in the past week, with a -19.37% drop in the past month, and a -55.53% fall in the past quarter. The volatility ratio for the week is 12.87%, and the volatility levels for the past 30 days are at 17.60% for RVPH. The simple moving average for the past 20 days is 16.79% for RVPH’s stock, with a -33.78% simple moving average for the past 200 days.
Analysts’ Opinion of RVPH
Many brokerage firms have already submitted their reports for RVPH stocks, with ROTH MKM repeating the rating for RVPH by listing it as a “Buy.” The predicted price for RVPH in the upcoming period, according to ROTH MKM is $12 based on the research report published on September 20, 2023 of the previous year 2023.
The Benchmark Company, on the other hand, stated in their research note that they expect to see RVPH reach a price target of $17. The rating they have provided for RVPH stocks is “Speculative Buy” according to the report published on June 08th, 2023.
H.C. Wainwright gave a rating of “Buy” to RVPH, setting the target price at $10 in the report published on January 24th of the previous year.
RVPH Trading at -22.06% from the 50-Day Moving Average
After a stumble in the market that brought RVPH to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -79.84% of loss for the given period.
Volatility was left at 17.60%, however, over the last 30 days, the volatility rate increased by 12.87%, as shares sank -23.65% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -58.12% lower at present.
During the last 5 trading sessions, RVPH rose by +14.43%, which changed the moving average for the period of 200-days by -26.26% in comparison to the 20-day moving average, which settled at $0.7387. In addition, Reviva Pharmaceuticals Holdings Inc saw -52.34% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for RVPH
The total capital return value is set at -34.16. Equity return is now at value -916.17, with -152.63 for asset returns.
Based on Reviva Pharmaceuticals Holdings Inc (RVPH), the company’s capital structure generated 0.36 points at debt to capital in total, while cash flow to debt ratio is standing at -73.22. The debt to equity ratio resting at 0.56. The interest coverage ratio of the stock is -1665.07.
Currently, EBITDA for the company is -29.88 million with net debt to EBITDA at 0.6. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.01.
Conclusion
In conclusion, Reviva Pharmaceuticals Holdings Inc (RVPH) has had a bad performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
